TU Dresden

CRTD receives 1.56 Mill. Euro BMBF-funding for retinal disease research
The research groups lead by Prof. Dr. Elly Tanaka, Prof. Dr. Marius Ader and Dr. Mike Karl at the CRTD have received funding with their CLEANSIGHT research team.  [read more]
First Dresdner Aktionstag Demenz at the CRTD attracted more than 100 visitors
On May 10th, 2017 - the CRTD, together with the Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Universitätsklinikum Carl Gustav Carus Dresden, and the Volkshochschule Dresden e.V.,... [read more]
CRTD Group leader Professor Sebastian Zeißig honored with the Theodor-Frerichs-Preis of the Deutsche Gesellschaft für Innere Medizin
With this prize, the expert association for internists honors Sebastian Zeißig’s outstanding research on the causes of colon cancer. In 2016, the group of Prof. Zeißig proved the decisive role of gut... [read more]
© Kenneth Peuker
Dresden vocational students gain practical insights into research at the CRTD
On the 24th April 2017, seven students from the vocational school center 'Ernst Lößnitzer' in Dresden began their practical training (internship) at the CRTD.  [read more]

At the DFG-Center for Regenerative Therapies Dresden (CRTD), our mission is to understand the biology of stem cells and physiological and pathological tissue and organ repair in order to develop new treatments for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, haematological diseases, such as leukemia, metabolic diseases, such as diabetes, and bone diseases. Our scientists are encouraged to think outside the box and to explore untapped areas of knowledge in the regenerative potential of the human body, and to apply this knowledge to prevent or reverse disease processes.

To achieve our aims, we strongly support interdisciplinary research, with eighteen core groups in a network of 87 principal investigators from diverse research institutes on the Dresden campus, with expertise in everything from the biology of cells and tissues to biomaterials to nanoengineering. CRTD has become a major driving force on campus and is ready to meet the challenges of moving new interventional strategies from bench to bedside.